Vycor Medical, Inc. (OTCQB: VYCO) announced financial results for the year ended December 31, 2025, showing revenue growth of 17% to $1.86 million, primarily driven by an 18% increase in the Vycor Medical division. The company achieved an operating profit of $33,900, compared to an operating loss of $9,145 in 2024, and a non-GAAP operating profit of $145,881, up from $81,245.
The Vycor Medical division, which markets the ViewSite Brain Access System (VBAS), saw revenue rise to $1.80 million, with most growth coming from international markets, a key strategic focus. Gross profit for the division was $1.50 million, with a margin of 83%, down from 89% due to validation, shipping, and higher manufacturing costs, as well as a higher international sales mix. The NovaVision division, still in development, reported revenue of $67,330, down 8% from 2024, with a gross margin of 93%.
During 2025, seven new peer-reviewed studies were published on VBAS, bringing the total to 50 peer-reviewed papers and 14 other clinical papers. These studies, from the US, UK, Japan, and Mexico, highlighted VBAS's clinical advantages in reducing brain tissue damage, improving patient outcomes, and reducing hospital stays. Additionally, a new study on NovaVision's NeuroEyeCoach was published, comparing home-based and clinic-based use. The study found meaningful improvements in both settings with no significant differences, validating NeuroEyeCoach as an effective tool for remote therapy. This is particularly relevant given the global trend toward digital healthcare at home.
On a GAAP basis, operating expenses were $1.53 million, including non-cash charges of $63,143 for depreciation and $48,838 for stock-based compensation. Non-GAAP cash operating expenses were $1.42 million, resulting in a non-GAAP operating profit of $145,881. The company reported a net loss of $396,796, or $0.01 per share, on a GAAP basis, and a non-GAAP net loss of $284,815. The weighted average shares outstanding were 33.37 million.
Vycor Medical continues to focus on expanding its VBAS product internationally and developing NovaVision's vision rehabilitation therapies. The company's VBAS system is used in over 350 US hospitals and numerous international locations, protected by 49 issued and 8 pending patents. NovaVision's Visual Restoration Therapy is the only FDA-cleared therapy for vision rehabilitation following neurological brain damage, and its NeuroEyeCoach program has been clinically supported by a 296-patient study showing improvement in over 80% of patients.
For more information, visit www.vycormedical.com, www.vycorvbas.com, or www.novavision.com.
